- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
Patent holdings for IPC class C07D 319/18
Total number of patents in this class: 277
10-year publication summary
|
20
|
19
|
15
|
23
|
16
|
15
|
9
|
14
|
21
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Biosplice Therapeutics, Inc. | 170 |
10 |
| CHDI Foundation, Inc. | 106 |
9 |
| Agios Pharmaceuticals, Inc | 216 |
6 |
| Bristol-myers Squibb Company | 4867 |
5 |
| Merck Patent GmbH | 5820 |
5 |
| Cancer Research Technology Limited | 526 |
5 |
| Genzyme Corporation | 1277 |
5 |
| The Scripps Research Institute | 1346 |
5 |
| Taisho Pharmaceutical Co., Ltd. | 866 |
5 |
| Toyama Chemical Co., Ltd. | 102 |
5 |
| Enveric Biosciences Canada Inc. | 62 |
5 |
| Lapix Therapeutics, Inc. | 17 |
5 |
| F. Hoffmann-La Roche AG | 7942 |
4 |
| Allergan, Inc. | 2339 |
4 |
| BioMarin Pharmaceutical Inc. | 374 |
4 |
| ChemoCentryx, Inc. | 385 |
4 |
| Exonhit Therapeutics SA | 25 |
4 |
| Tianjin Chasesun Pharmaceutical Co., Ltd | 13 |
4 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2866 |
4 |
| Boehringer Ingelheim International GmbH | 4640 |
3 |
| Other owners | 176 |